In normal cells, EphA2 is degraded after phosphorylation; however, in tumor cells, EphA2 is dephosphorylated and found to be highly associated with the development of various types of cancer11,14, including cervical cancer15, ovarian cancer16, colon cancer17, breast cancer18, non-small-cell lung cancer19 and prostate cancer20. This evidence concerns the gene EPHA2 and neoplasm.